-
Manufacturing, Supply Chain & Infrastructure1 week agoGilead launches research facility in US for new medicine development
The new facility expands the company’s capabilities in inflammation, oncology and data science. Gilead currently employs 11,000 people in the US, with more than 7,400 based...
-
Regulatory Intelligence & Drug Approvals1 week agoFDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly...
-
AI, Machine Learning & Computational Biology1 week agoLSTM opens $23m robotic AI lab for infection research
The Liverpool Accelerate Laboratory was developed with the LSTM-led iiCON: Infection Innovation Consortium and received funding from the Liverpool City Region Combined Authority. It is due...
-
Capital, M&A & Industry Strategy1 week agoNovartis India acquires Pfizer brands for $132m
The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement...
-
Manufacturing, Supply Chain & Infrastructure2 weeks agoAtomVie opens $160m radiopharmaceutical manufacturing facility in Ontario
The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date. It...
-
Regulatory Intelligence & Drug Approvals2 weeks agoFDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1)...
-
Capital, M&A & Industry Strategy2 weeks agoSuperluminal Medicines secures $60m to advance rare obesity therapy
The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli...
-
Global Biotechnology & Pharmaceutical Markets2 weeks agoMédunik and Biocodex sign exclusive agreement for Diacomit in Canada
The agreement gives Médunik Canada immediate responsibility for Diacomit’s sales, marketing, and medical affairs activities throughout the country. It aims to leverage Médunik Canada’s network and...
-
Drug Discovery & Therapeutics2 weeks agoBiocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule
The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience...
-
Capital, M&A & Industry Strategy2 weeks agoNovartis signs deal with Alteogen for drug delivery
The deal allows Novartis to exercise multiple options for exclusive global rights to develop subcutaneous versions of several of its products employing the berahyaluronidase alfa enzyme,...
FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Novo’s Denecimig Demonstrates Tolerability After Switch from Emicizumab in FRONTIER5 Study of People with Haemophilia A as Published in the Journal of Thrombosis and Haemostasis
Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
